-
Mashup Score: 5What Every Urologist Should Know About UGN-101 Treatment and its Real-World Implications for Urothelial Cancer - Hristos Kaimakliotis - 19 day(s) ago
Sam Chang engages in a detailed discussion with Hristos Kaimakliotis, who presents findings from a multi-institutional review he authored, focusing on real-world practices with Jelmyto, a treatment for upper tract urothelial cancer. The study explores the efficacy of mitomycin reverse thermal gel, UGN-101, which has shown promise in ablating low-grade upper tract urothelial cancer. The OLYMPUS…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- – If approved,…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 5What Every Urologist Should Know About UGN-101 Treatment and its Real-World Implications for Urothelial Cancer - Hristos Kaimakliotis - 2 month(s) ago
Sam Chang engages in a detailed discussion with Hristos Kaimakliotis, who presents findings from a multi-institutional review he authored, focusing on real-world practices with Jelmyto, a treatment for upper tract urothelial cancer. The study explores the efficacy of mitomycin reverse thermal gel, UGN-101, which has shown promise in ablating low-grade upper tract urothelial cancer. The OLYMPUS…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 16
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostMarkus Eckstein@Markuseckstein3FGFR3 mutations are frequent alterations in urothelial cancer, but : NMIBC: ~50% are mutated MIBC: ~10% are mutated UTUC stage independent: ~ 30% are mutated mUC (=bc + UTUC): ~15-20 % are mutated Fusions are very rare throughout all entities! Frequency is ~1% to…
Source: x.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 13
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostMarkus Eckstein@Markuseckstein3FGFR3 mutations are frequent alterations in urothelial cancer, but : NMIBC: ~50% are mutated MIBC: ~10% are mutated UTUC stage independent: ~ 30% are mutated mUC (=bc + UTUC): ~15-20 % are mutated Fusions are very rare throughout all entities! Frequency is ~1% to…
Source: x.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 5What Every Urologist Should Know About UGN-101 Treatment and its Real-World Implications for Urothelial Cancer - Hristos Kaimakliotis - 3 month(s) ago
Sam Chang engages in a detailed discussion with Hristos Kaimakliotis, who presents findings from a multi-institutional review he authored, focusing on real-world practices with Jelmyto, a treatment for upper tract urothelial cancer. The study explores the efficacy of mitomycin reverse thermal gel, UGN-101, which has shown promise in ablating low-grade upper tract urothelial cancer. The OLYMPUS…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy – – If approved,…
Source: newsroom.astellas.usCategories: General Medicine News, PayerTweet
-
Mashup Score: 3
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival – – If approved, PADCEV with KEYTRUDA would be the first combination in the EU to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line locally advanced or metastatic urothelial cancer – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review a Type II variation application for PADCEV ® (enfortumab vedotin) with KEYTRUDA ® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If approved, PADCEV with KEYTRUDA has the potential to change the treatment paradigm, becoming the first combination treatment to offer an alternative to platinum-containing
Source: www.pfizer.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2Atezolizumab, With or Without Chemo, Did Not Improve OS in Advanced Urothelial Cancer - Oncology Nurse Advisor - 3 month(s) ago
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5What Every Urologist Should Know About UGN-101 Treatment and its Real-World Implications for Urothelial Cancer - Hristos Kaimakliotis - 4 month(s) ago
Sam Chang engages in a detailed discussion with Hristos Kaimakliotis, who presents findings from a multi-institutional review he authored, focusing on real-world practices with Jelmyto, a treatment for upper tract urothelial cancer. The study explores the efficacy of mitomycin reverse thermal gel, UGN-101, which has shown promise in ablating low-grade upper tract urothelial cancer. The OLYMPUS…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
What every urologist should know about UGN-101 treatment and its real-world implications for #UrothelialCancer. Hristos Kaimakliotis, MD @IUMedSchool joins @UroCancerMD to discuss findings focusing on real-world practices with @jelmyto > https://t.co/Q9dyXCKaTC @UroGenPharma https://t.co/vD59jU6tcy